Research on Southwest Florida cyanobacterial blooms shows that airborne cyanobacterial toxins contain the neurotoxin 2,4-DAB, which is linked to Alzheimer's disease and ALS. The study suggests chronic low-level exposure through breathing may be a significant risk factor for these diseases.
A new rapid blood test for ALS has been developed by Brain Chemistry Labs, providing 97% accuracy in diagnosing the disease from a single blood draw. The test is based on microRNA analysis and can also rule out patients without ALS, offering hope to those struggling with this debilitating condition.
A study found that stranded dolphins in Florida had Alzheimer's-type neuropathology and disorientation, likely caused by chronic exposure to toxic cyanobacterial toxins. The toxins were associated with misfolded tau proteins and amyloid plaques characteristic of the disease.
Scientists at Brain Chemistry Labs discovered a promising compound called kalata B1 from violets that enhances the activity of chemotherapy TMZ against glioblastoma cells. The synthetic version of kalata B1 showed equal efficacy to the natural molecule, offering a potential new treatment option for patients.
A highly accurate diagnostic blood test has been developed for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects neurons in the brain and spinal cord. The test requires only a simple blood draw and can distinguish between ALS patients and healthy controls with an overall accuracy of up to 98%.
Researchers have identified BMAA, a chronic neurotoxin linked to ALS and Alzheimer's, in dust particles from the Great Salt Lake. This dust poses an environmental health risk due to its inhalation potential.
A simple blood test for ALS has been developed using microRNA analysis, which can accurately identify patients with the disease. The test uses a unique protein called L1CAM to concentrate diagnostic particles from extracellular vesicles in the bloodstream.
Researchers at Brain Chemistry Labs have developed a new blood test for ALS using microRNA sequences, which accurately discriminated between patients and healthy individuals. The test works even with varying environmental conditions, offering hope for rapid diagnosis and improved patient outcomes.
A unique ratio of metabolites in blood samples may facilitate faster diagnosis of early-stage Alzheimer's disease. The discovery promises to reduce reliance on amyloid fragments, which can be detected using existing equipment.
Researchers discovered that cyclotides from violets increase the power of TMZ in killing glioblastoma cancer cells by up to eight-fold. This breakthrough could lead to better treatment options for patients with this fatal form of brain cancer.
Cyanobacteria from Lake Okeechobee released toxins such as microcystin-LR, brevetoxin, and BMAA, potentially exposing coastal residents to adverse health effects. Chronic exposure to multiple toxins is a growing concern for human and animal health.
Researchers analyze dried cyanobacteria wafers from Lake Chad for toxins, finding safety concerns but also nutritional benefits. Dihe cakes are a rich source of dietary amino acids and may help undernourished villagers.
Researchers at Brain Chemistry Labs have developed a new blood test that can diagnose ALS earlier than current methods, using brain exosomes and microRNA. The test, based on genetic material shed by different tissues, distinguishes between ALS patients and healthy controls with high accuracy.
A new study published in the Journal of Neuropathology & Experimental Neurology suggests that amino acid L-serine may be useful in treating ALS. The study found that L-serine successfully reduced ALS-like changes in an animal model of ALS, including motor neuron degeneration and pro-inflammatory microglia.